- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07939698
Individualized Brain Stimulation for Irritable Bowel Syndrome With Depressive Symptoms
Effects of Individualized Resting-State fMRI-Guided Intermittent Theta-Burst Stimulation on Depressive and Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome: A Randomized, Double-Blind, Sham-Controlled Trial
This randomized, double-blind, sham-controlled trial aims to evaluate the effects of individualized intermittent theta-burst stimulation (iTBS) on depressive and gastrointestinal symptoms in patients with irritable bowel syndrome (IBS) and depressive symptoms.
A total of 60 eligible participants will be randomly assigned in a 1:1 ratio to active or sham stimulation. Individualized stimulation targets within the left dorsolateral prefrontal cortex (DLPFC) will be identified using resting-state functional magnetic resonance imaging (fMRI).
Participants will receive 10 stimulation sessions over two weeks. Clinical assessments and multimodal brain MRI will be performed at baseline and at the end of Week 2. The primary outcome will be the change in depressive symptom severity measured by the 17-item Hamilton Depression Rating Scale (HAMD-17).
An optional ancillary study involving paired stool sample collection at baseline and Week 2 is planned to support future exploratory investigations of gut microbiota and its associations with clinical symptoms and brain network characteristics. This ancillary component will be implemented only after the relevant ethics approval and additional informed consent have been obtained.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Jie Li
- Telefonnummer: +8615988858667
- E-post: jie_sweethz@163.com
Studieorter
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310015
- Rekrytering
- The Affiliated Hospital of Hangzhou Normal University
-
Kontakt:
- Jie Li
- Telefonnummer: +8615988858667
- E-post: jie_sweethz@163.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Right-handed individuals.
- Diagnosis of irritable bowel syndrome according to the Rome IV criteria.
- Presence of depressive symptoms, defined as a HAMD-17 score greater than 7.
- Inadequate response to at least two months of conventional treatment for IBS.
- Ability to understand the study procedures and provide written informed consent.
- Willingness and ability to undergo MRI examinations and complete the study assessments.
Exclusion Criteria:
- Contraindications to MRI or transcranial magnetic stimulation.
- Known food intolerance, relevant gastrointestinal surgery, or gastrointestinal diseases other than IBS that may explain the symptoms.
- History of significant neurological disorders or psychiatric disorders other than the depressive symptoms under investigation.
- History of intracranial surgery.
- Intracranial mass lesions or severe white matter abnormalities detected by MRI.
- Other conditions that, in the investigator's judgment, would make participation inappropriate or unsafe.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Active Individualized iTBS
Participants will receive individualized intermittent theta-burst stimulation targeting the left dorsolateral prefrontal cortex. The stimulation target will be identified using resting-state fMRI-guided functional connectivity analysis. Stimulation will be delivered at 90% of the resting motor threshold, with 1,800 pulses per session. Each session will comprise three blocks of 600 pulses, separated by approximately 15-minute intervals. Participants will receive five sessions per week for two weeks, for a total of 10 sessions. |
Resting-state fMRI-guided iTBS targeting the individualized left dorsolateral prefrontal cortex at 90% of resting motor threshold, delivering 1,800 pulses per session for 10 sessions over two weeks. |
|
Sham Comparator: Sham iTBS
Participants will undergo a sham stimulation procedure with a schedule comparable to the active intervention. The stimulation coil will be positioned at 90 degrees to minimize effective cortical stimulation. Participants will receive five sessions per week for two weeks, for a total of 10 sessions. |
A sham stimulation procedure using a coil positioned at 90 degrees, with a treatment schedule comparable to active iTBS. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change From Baseline in Depressive Symptom Severity Assessed by HAMD-17 at Week 2
Tidsram: Baseline and end of Week 2
|
Depressive symptom severity will be assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17). A higher score indicates greater depressive symptom severity. The change from baseline to the end of Week 2 will be compared between the active and sham stimulation groups. |
Baseline and end of Week 2
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change From Baseline in IBS Symptom Severity at Week 2
Tidsram: Baseline and end of Week 2
|
IBS symptom severity will be assessed using the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS). Changes from baseline to the end of Week 2 will be compared between groups. |
Baseline and end of Week 2
|
|
Change From Baseline in Abdominal Pain Intensity at Week 2
Tidsram: Baseline and end of Week 2
|
Abdominal pain intensity will be evaluated using a Visual Analog Scale (VAS). |
Baseline and end of Week 2
|
|
Change From Baseline in Pain Severity Assessed by the Short-Form McGill Pain Questionnaire at Week 2
Tidsram: Baseline and end of Week 2
|
Pain-related symptoms will be assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ). |
Baseline and end of Week 2
|
|
Change From Baseline in Anxiety Symptom Severity at Week 2
Tidsram: Baseline and end of Week 2
|
Anxiety symptom severity will be assessed using the 14-item Hamilton Anxiety Rating Scale (HAMA-14). |
Baseline and end of Week 2
|
|
Change From Baseline in IBS-Related Quality of Life at Week 2
Tidsram: Baseline and end of Week 2
|
IBS-related quality of life will be assessed using the Irritable Bowel Syndrome Quality of Life questionnaire (IBS-QOL). |
Baseline and end of Week 2
|
|
MRI Outcomes
Tidsram: Baseline and end of Week 2
|
functional and structural brain network analyses |
Baseline and end of Week 2
|
|
Safety Outcomes
Tidsram: Baseline and end of Week 2
|
adverse-event incidence |
Baseline and end of Week 2
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- IBS_dep-iTBS-2025
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .